Karla Mathias de Almeida

Karla Mathias de Almeida

Auto-generated profile, based on publicly available information

Karla Mathias de Almeida

Universidade de São Paulo (USP), Brazil

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 February 2011 in CNS Neuroscience & Therapeutics
Verified
Journal Article
Closed access
PDF file
KAKarla M. de Almeida
Karla M. de Almeida
CMCamila L. R. L. Moreira
Camila L. R. L. Moreira
BLBeny Lafer
Beny Lafer

1 February 2012 in Comprehensive Psychiatry
Verified
Journal Article
Closed access
LALena Nabuco de Abreu
Lena Nabuco de Abreu
FNFabiano G. Nery
Fabiano G. Nery
JHJill M. Harkavy-Friedman
Jill M. Harkavy-Friedman
KAKarla Matias de Almeida
Karla Matias de Almeida
BGBernardo Carramao Gomes
Bernardo Carramao Gomes
BLBeny Lafer
Beny Lafer

1 March 2006 in Brazilian Journal of Psychiatry
Verified
Journal Article
Open access
PDF file
RMRicardo Alberto Moreno
Ricardo Alberto Moreno
CTChei Tung Teng
Chei Tung Teng
KAKarla Mathias de Almeida
Karla Mathias de Almeida
HJHildeberto Tavares Junior
Hildeberto Tavares Junior
OBJETIVE: Hypericum perforatum has demonstrated antidepressant efficacy when compared to placebo, but comparisons with other antidepressants remain controversial. We assessed the efficacy and safety of Hypericum perforatum in comparison with fluoxetine, in a 8-week double-blind trial in patients with mild to moderate depression. METHOD: Seventy-two outpatients were randomly assigned to receive Hypericum perforatum 900 mg/day, fluoxetine 20 mg/day or placebo. Efficacy measures included the HAM-D21 scale, the Montgomery-Åsberg Rating Scale, and the Clinical Global Impression. Safety was assessed with the UKU Side Effect Rating Scale. RESULTS: Intention-to-treat analysis showed no differences between the mean scores of the three groups. In the analyses of observed cases, patients receiving Hypericum perforatum had the lowest remission rates (12%, p = 0.016) compared to fluoxetine (34.6%) and placebo (45%). CONCLUSIONS: Hypericum perforatum was less efficacious than both fluoxetine and placebo. Both drugs were safe and well-tolerated. Larger trials are needed for definite conclusions.

1 July 2016 in Comprehensive Psychiatry
Verified
Journal Article
Closed access
FFFrancy de Brito Ferreira Fernandes
Francy de Brito Ferreira Fernandes
AGAlexandre Duarte Gigante
Alexandre Duarte Gigante
MBMariangeles Berutti
Mariangeles Berutti
JAJosé Antônio Amaral
José Antônio Amaral
KAKarla Mathias de Almeida
Karla Mathias de Almeida
FNFabiano Gonçalves Nery
Fabiano Gonçalves Nery

8 January 2016 in Brazilian Journal of Psychiatry
Verified
Journal Article
Open access
GMGustavo C. Medeiros
Gustavo C. Medeiros
SSSofia B. Senço
Sofia B. Senço
BLBeny Lafer
Beny Lafer
KAKarla M. Almeida
Karla M. Almeida
Bipolar disorder (BD) is often left untreated for long periods, and this delay in treatment correlates with unfavorable prognosis. The present study sought to assess the magnitude of duration of untreated bipolar disorder (DUB) in Brazil. We hypothesized that DUB would be longer in Brazil than in developed countries, and would be associated with poor clinical outcomes. One hundred and fifty-two psychiatric outpatients were evaluated for BD diagnosis, demographics, DUB, and clinical outcomes. The mean age and mean DUB were, respectively, 38.9±10.8 and 10.4±9.8 years. An extended DUB was associated with early onset of BD (p < 0.001), depression as first mood episode (p = 0.04), and presence of BD in a first-degree relative (p = 0.012). Additionally, a longer DUB was associated with poorer clinical outcomes, such as elevated rates of rapid cycling (p = 0.004) and anxiety disorders (p = 0.016), as well as lower levels of current full remission (p = 0.021). As DUB may be a modifiable variable, better medical education regarding mental health, more structured medical services, and population-wide psychoeducation might reduce the time between onset and proper management of BD, thus improving outcome.

1 June 2013 in Brazilian Journal of Psychiatry
Verified
Journal Article
Open access
PDF file
FGFabiano A. Gomes
Fabiano A. Gomes
KAKarla M. Almeida
Karla M. Almeida
PMPedro V. Magalhães
Pedro V. Magalhães
SCSheila Caetano
Sheila Caetano
MKMárcia Kauer-Sant'ANna
Márcia Kauer-Sant'ANna
FKFlávio Kapczinski
Flávio Kapczinski
Key words: Bipolar disorder; cardiovascular risk factors; comorbidity